200 related articles for article (PubMed ID: 25400013)
1. Psychometrics evaluation of Charcot-Marie-Tooth Neuropathy Score (CMTNSv2) second version, using Rasch analysis.
Sadjadi R; Reilly MM; Shy ME; Pareyson D; Laura M; Murphy S; Feely SM; Grider T; Bacon C; Piscosquito G; Calabrese D; Burns TM
J Peripher Nerv Syst; 2014 Sep; 19(3):192-6. PubMed ID: 25400013
[TBL] [Abstract][Full Text] [Related]
2. Validation of the Italian version of the Charcot-Marie-Tooth Health Index.
Pisciotta C; Ciafaloni E; Zuccarino R; Calabrese D; Saveri P; Fenu S; Tramacere I; Genovese F; Dilek N; Johnson NE; Heatwole C; Herrmann DN; Pareyson D;
J Peripher Nerv Syst; 2020 Sep; 25(3):292-296. PubMed ID: 32511835
[TBL] [Abstract][Full Text] [Related]
3. A Rasch Analysis of the Charcot-Marie-Tooth Neuropathy Score (CMTNS) in a Cohort of Charcot-Marie-Tooth Type 1A Patients.
Wang W; Guedj M; Bertrand V; Foucquier J; Jouve E; Commenges D; Proust-Lima C; Murphy NP; Blin O; Magy L; Cohen D; Attarian S
PLoS One; 2017; 12(1):e0169878. PubMed ID: 28095456
[TBL] [Abstract][Full Text] [Related]
4. Transitioning outcome measures: relationship between the CMTPedS and CMTNSv2 in children, adolescents, and young adults with Charcot-Marie-Tooth disease.
Burns J; Menezes M; Finkel RS; Estilow T; Moroni I; Pagliano E; Laurá M; Muntoni F; Herrmann DN; Eichinger K; Shy R; Pareyson D; Reilly MM; Shy ME
J Peripher Nerv Syst; 2013 Jun; 18(2):177-80. PubMed ID: 23781965
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of the Charcot-Marie-Tooth Disease Infant Scale.
Mandarakas MR; Menezes MP; Rose KJ; Shy R; Eichinger K; Foscan M; Estilow T; Kennedy R; Herbert K; Bray P; Refshauge K; Ryan MM; Yiu EM; Farrar M; Sampaio H; Moroni I; Pagliano E; Pareyson D; Yum SW; Herrmann DN; Acsadi G; Shy ME; Burns J; Sanmaneechai O
Brain; 2018 Dec; 141(12):3319-3330. PubMed ID: 30476010
[TBL] [Abstract][Full Text] [Related]
6. Validation of the Italian version of the Charcot-Marie-Tooth disease Pediatric Scale.
Zuccarino R; Prada V; Moroni I; Pagliano E; Foscan M; Robbiano G; Pisciotta C; Cornett K; Shy R; Schenone A; Pareyson D; Shy M; Burns J
J Peripher Nerv Syst; 2020 Jun; 25(2):138-142. PubMed ID: 32394473
[TBL] [Abstract][Full Text] [Related]
7. Selected items from the Charcot-Marie-Tooth (CMT) Neuropathy Score and secondary clinical outcome measures serve as sensitive clinical markers of disease severity in CMT1A patients.
Mannil M; Solari A; Leha A; Pelayo-Negro AL; Berciano J; Schlotter-Weigel B; Walter MC; Rautenstrauss B; Schnizer TJ; Schenone A; Seeman P; Kadian C; Schreiber O; Angarita NG; Fabrizi GM; Gemignani F; Padua L; Santoro L; Quattrone A; Vita G; Calabrese D; ; Young P; Laurà M; Haberlová J; Mazanec R; Paulus W; Beissbarth T; Shy ME; Reilly MM; Pareyson D; Sereda MW
Neuromuscul Disord; 2014 Nov; 24(11):1003-17. PubMed ID: 25085517
[TBL] [Abstract][Full Text] [Related]
8. Motor unit number index correlates with disability in Charcot-Marie-Tooth disease.
Bas J; Delmont E; Fatehi F; Salort-Campana E; Verschueren A; Pouget J; Lefebvre MN; Grapperon AM; Attarian S
Clin Neurophysiol; 2018 Jul; 129(7):1390-1396. PubMed ID: 29729594
[TBL] [Abstract][Full Text] [Related]
9. Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease.
Murphy SM; Herrmann DN; McDermott MP; Scherer SS; Shy ME; Reilly MM; Pareyson D
J Peripher Nerv Syst; 2011 Sep; 16(3):191-8. PubMed ID: 22003934
[TBL] [Abstract][Full Text] [Related]
10. Plasma neurofilament light chain level is not a biomarker of Charcot-Marie-Tooth disease progression: Results of 3-year follow-up study.
Setlere S; Grosmane A; Kurjane N; Gailite L; Rots D; Blennow K; Zetterberg H; Kenina V
Eur J Neurol; 2023 Aug; 30(8):2453-2460. PubMed ID: 37165526
[TBL] [Abstract][Full Text] [Related]
11. Quantifying gait impairment in individuals affected by Charcot-Marie-Tooth disease: the usefulness of gait profile score and gait variable score.
Coghe G; Pau M; Mamusa E; Pisano C; Corona F; Pilloni G; Porta M; Marrosu G; Vannelli A; Frau J; Lorefice L; Fenu G; Marrosu MG; Cocco E
Disabil Rehabil; 2020 Mar; 42(5):737-742. PubMed ID: 30334469
[No Abstract] [Full Text] [Related]
12. Utility of Charcot-Marie-Tooth Neuropathy Score in children with type 1A disease.
Haberlová J; Seeman P
Pediatr Neurol; 2010 Dec; 43(6):407-10. PubMed ID: 21093731
[TBL] [Abstract][Full Text] [Related]
13. Neural cell adhesion molecule 1 is a cellular target engaged plasma biomarker in demyelinating Charcot-Marie-Tooth disease.
Kim YH; Yoon BA; Jo YR; Nam SH; Kim NH; Kim KH; Kim JK; Choi BO; Park HT
Eur J Neurol; 2023 Jun; 30(6):1745-1754. PubMed ID: 36856547
[TBL] [Abstract][Full Text] [Related]
14. Reliability of the Charcot-Marie-Tooth functional outcome measure.
Bray P; Cornett KMD; Estilow T; Pareyson D; Zuccarino R; Skorupinska M; Pipis M; Sowden JE; Scherer S; Reilly MM; Shy ME; Herrmann DN; Burns J; Eichinger KJ
J Peripher Nerv Syst; 2020 Sep; 25(3):288-291. PubMed ID: 32844461
[TBL] [Abstract][Full Text] [Related]
15. A longitudinal study of CMT1A using Rasch analysis based CMT neuropathy and examination scores.
Fridman V; Sillau S; Acsadi G; Bacon C; Dooley K; Burns J; Day J; Feely S; Finkel RS; Grider T; Gutmann L; Herrmann DN; Kirk CA; Knause SA; Laurá M; Lewis RA; Li J; Lloyd TE; Moroni I; Muntoni F; Pagliano E; Pisciotta C; Piscosquito G; Ramchandren S; Saporta M; Sadjadi R; Shy RR; Siskind CE; Sumner CJ; Walk D; Wilcox J; Yum SW; Züchner S; Scherer SS; Pareyson D; Reilly MM; Shy ME;
Neurology; 2020 Mar; 94(9):e884-e896. PubMed ID: 32047073
[TBL] [Abstract][Full Text] [Related]
16. Reliability and validity of the CMT neuropathy score as a measure of disability.
Shy ME; Blake J; Krajewski K; Fuerst DR; Laura M; Hahn AF; Li J; Lewis RA; Reilly M
Neurology; 2005 Apr; 64(7):1209-14. PubMed ID: 15824348
[TBL] [Abstract][Full Text] [Related]
17. The Charcot-Marie-Tooth Health Index: Evaluation of a Patient-Reported Outcome.
Johnson NE; Heatwole C; Creigh P; McDermott MP; Dilek N; Hung M; Bounsanga J; Tang W; Shy ME; Herrmann DN
Ann Neurol; 2018 Aug; 84(2):225-233. PubMed ID: 30014533
[TBL] [Abstract][Full Text] [Related]
18. MRI biomarker assessment of neuromuscular disease progression: a prospective observational cohort study.
Morrow JM; Sinclair CD; Fischmann A; Machado PM; Reilly MM; Yousry TA; Thornton JS; Hanna MG
Lancet Neurol; 2016 Jan; 15(1):65-77. PubMed ID: 26549782
[TBL] [Abstract][Full Text] [Related]
19. Plasma neurofilament light chain as a potential biomarker in Charcot-Marie-Tooth disease.
Millere E; Rots D; Simrén J; Ashton NJ; Kupats E; Micule I; Priedite V; Kurjane N; Blennow K; Gailite L; Zetterberg H; Kenina V
Eur J Neurol; 2021 Mar; 28(3):974-981. PubMed ID: 33340200
[TBL] [Abstract][Full Text] [Related]
20. A rat model of Charcot-Marie-Tooth disease 1A recapitulates disease variability and supplies biomarkers of axonal loss in patients.
Fledrich R; Schlotter-Weigel B; Schnizer TJ; Wichert SP; Stassart RM; Meyer zu Hörste G; Klink A; Weiss BG; Haag U; Walter MC; Rautenstrauss B; Paulus W; Rossner MJ; Sereda MW
Brain; 2012 Jan; 135(Pt 1):72-87. PubMed ID: 22189569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
